Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours

Endocrine-Related Cancer

Volumn 23, Issue 9, 2016, Pages R423-R436

  Dimitriadis, Georgios K ^a,b,c   Weickert, Martin O ^a,b,d   Randeva, Harpal S ^a,b,d   Kaltsas, Gregory ^a,e,f   Grossman, Ashley ^f  

^a University Hospitals of Coventry   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d Faculty of Engineering and Computing   (United Kingdom)

^e UNIVERSITY OF ATHENS   (Greece)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Carcinoid syndrome; Ectopic hormonal secretion; Glucagonoma; Insulinoma; Neuroendocrine tumours; Secretory syndrome; VIPoma

Indexed keywords

SECRETORY COMPONENT; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN;

CANCER CHEMOTHERAPY; CANCER MORTALITY; CARCINOID SYNDROME; CAUSE OF DEATH; DISEASE ASSOCIATION; GASTRINOMA; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GLUCAGONOMA; HUMAN; INSULINOMA; NONHUMAN; PALLIATIVE THERAPY; PARANEOPLASTIC SYNDROME; PHEOCHROMOCYTOMA; REVIEW; SOMATOSTATINOMA; VIPOMA; ZOLLINGER ELLISON SYNDROME; ANALOGS AND DERIVATIVES; ECTOPIC HORMONE PRODUCTION; GASTROINTESTINAL TUMOR; NEUROENDOCRINE TUMOR; PANCREAS TUMOR;

GASTROINTESTINAL NEOPLASMS; HUMANS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PARANEOPLASTIC ENDOCRINE SYNDROMES; SOMATOSTATIN;

EID: 84989306591     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-16-0200     Document Type: Review

References (81)

1. Angeletti S, Corleto VD, Schillaci O, Marignani M, Annibale B, Moretti A, Silecchia G, Scopinaro F, Basso N, Bordi C, et al. 1998 Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut 42 792-794. (doi:10. 1136/ gut. 42. 6. 792)
2. Anthony L & Vinik AI 2011 Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period. Pancreas 40 987-994. (doi:10. 1097/MPA. 0b013e31821f66b4)
3. Anthony L, Johnson D, Hande K, Shaff M, Winn S, Krozely M & Oates J 1993 Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncologica 32 217-223. (doi:10. 3109/ 02841869309083915)
4. Aparicio T, Ducreux M, Baudin E, Sabourin JC, De Baere T, Mitry E, Schlumberger M & Rougier P 2001 Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. European Journal of Cancer 37 1014-1019. (doi:10. 1016/ S0959-8049(01)00073-9)
5. Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, Jurgensen R, Stein K, Schafer H, Bruns C, et al. 1996 Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 38 430-438. (doi:10. 1136/gut. 38. 3. 430)
6. Arnold R, Rinke A, Klose KJ, Muller HH, Wied M, Zamzow K, Schmidt C, Schade-Brittinger C, Barth P, Moll R, et al. 2005 Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clinical Gastroenterology and Hepatology 3 761-771. (doi:10. 1016/s1542-3565(05)00481-7)
7. Baldelli R, Barnabei A, Rizza L, Isidori AM, Rota F, Di Giacinto P, Paoloni A, Torino F, Corsello SM & Lenzi A 2014 Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives. Frontiers in Endocrinology 5 7. (doi:10. 3389/fendo. 2014. 00007)
8. Baratelli G, Brizzi MP, Tampellini M, Scagliotti GV, Priola A, Terzolo M, Pia A & Berruti A 2014 Intermitent everolimus administration for malignant insulinoma. Endocrinology, Diabetes & Metabolism Case Reports 2014 140047. (doi:10. 1530/edm-14-0047)
9. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ & Pless J 1982 SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sciences 31 1133-1140. (doi:10. 1016/0024-3205(82)90087-x)
10. Bernard V, Lombard-Bohas C, Taquet MC, Caroli-Bosc FX, Ruszniewski P, Niccoli P, Guimbaud R, Chougnet CN, Goichot B, Rohmer V, et al. 2013 Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia. European Journal of Endocrinology 168 665-674. (doi:10. 1530/EJE-12-1101)
11. Bhattacharyya S, Toumpanakis C, Chilkunda D, Caplin ME & Davar J 2011 Risk factors for the development and progression of carcinoid heart disease. American Journal of Cardiology 107 1221-1226. (doi:10. 1016/j. amjcard. 2010. 12. 025)
12. Bouma G, Van Faassen M, Kats-Ugurlu G, de Vries EG, Kema IP & Walenkamp AM 2015 Niacin (vitamin B3) supplementation in serotonin producing neuroendocrine tumor patients. Neuroendocrinology 103 489-494. (doi:10. 1159/000440621)
13. Bourcier ME & Vinik AI 2013 Sunitinib for the treatment of metastatic paraganglioma and vasoactive intestinal polypeptide-producing tumor (VIPoma). Pancreas 42 348-352. (doi:10. 1097/ MPA. 0b013e31825c53fa)
14. Broder MS, Beenhouwer D, Strosberg JR, Neary MP & Cherepanov D 2015 Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review. World Journal of Gastroenterology 21 1945-1955. (doi:10. 3748/ wjg. v21. i6. 1945)
15. Bruns C, Weckbecker G, Raulf F, Kaupmann K, Schoeffter P, Hoyer D & Lubbert H 1994 Molecular pharmacology of somatostatin-receptor subtypes. Annals of the New York Academy of Sciences 733 138-146. (doi:10. 1111/j. 1749-6632. 1994. tb17263. x)
16. Bruns C, Lewis I, Briner U, Meno-Tetang G & Weckbecker G 2002 SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. European Journal of Endocrinology 146 707-716. (doi:10. 1530/eje. 0. 1460707)
17. Cisco RM & Norton JA 2007 Surgery for gastrinoma. Advances in Surgery 41 165-176. (doi:10. 1016/j. yasu. 2007. 05. 010)
18. Condron ME, Pommier SJ & Pommier RF 2016 Continuous infusion of octreotide combined with perioperative octreotide bolus does not prevent intraoperative carcinoid crisis. Surgery 159 358-365. (doi:10. 1016/j. surg. 2015. 05. 036)
19. Connolly HM, Schaff HV, Mullany CJ, Rubin J, Abel MD & Pellikka PA 2001 Surgical management of left-sided carcinoid heart disease. Circulation 104 (Supplement 1) I36-I40. (doi:10. 1161/ hc37t1. 094898)
20. Crona J, Norlen O, Antonodimitrakis P, Welin S, STlberg P & Eriksson B 2016 Multiple and secondary hormonal secretion in patients with metastatic pancreatic neuroendocrine tumours. Journal of Clinical Endocrinology and Metabolism 101 445-452. (doi:10. 1210/jc. 2015-2436)
21. de Herder WW, van Schaik E, Kwekkeboom D & Feelders RA 2011 New therapeutic options for metastatic malignant insulinomas. Clinical Endocrinology 75 277-284. (doi:10. 1111/j. 1365-2265. 2011. 04145. x)
22. de Mestier L, Hentric O, Cros J, Walter T, Roquin G, Brixi H, Lombard-Bohas C, Hammel P, Diebold MD, Couvelard A, et al. 2015a Metachronous hormonal syndromes in patients with pancreatic neuroendocrine tumors: a case-series study. Annals of Internal Medicine 162 682-689. (doi:10. 7326/m14-2132)
23. de Mestier L, Walter T, Brixi H, Lombard-Bohas C & Cadiot G 2015b Sunitinib achieved fast and sustained control of VIPoma symptoms. European Journal of Endocrinology 172 K1-K3. (doi:10. 1530/eje-14-0682)
24. di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, Zilembo N & di Leo A 1996 Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 77 402-408. (doi:10. 1002/(sici)1097-0142(19960115)77:2<402:: aid-cncr25>3. 0. co;2-4)
25. Doherty GM 2005 Rare endocrine tumours of the GI tract. Best Practice & Research Clinical Gastroenterology 19 807-817. (doi:10. 1016/j. bpg. 2005. 05. 004)
26. Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B & International Lanreotide and Interferon Alfa Study Group 2003 Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group. Journal of Clinical Oncology 21 2689-2696. (doi:10. 1200/JCO. 2003. 12. 142)
27. Fazio N, de Braud F, Delle Fave G & Oberg K 2007 Interferon-alpha and somatostatin analog in patients with gastroenetropancreatic neuroendocrine carcinoma: single agent or combination? Annals of Oncology 18 13-19. (doi:10. 1093/annonc/mdl144)
28. Ferolla P, Faggiano A, Grimaldi F, Ferone D, Scarpelli G, Ramundo V, Severino R, Bellucci MC, Camera LM, Lombardi G, et al. 2012 Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses. Journal of Endocrinological Investigation 35 326-331.
29. Fiebrich HB, Van Den Berg G, Kema IP, Links TP, Kleibeuker JH, Van Beek AP, Walenkamp AM, Sluiter WJ & De Vries EG 2010 Deficiencies in fat-soluble vitamins in long-term users of somatostatin analogue. Alimentary Pharmacology & Therapeutics 32 1398-1404. (doi:10. 1111/j. 1365-2036. 2010. 04479. x)
30. Florio T 2011 Adult pituitary stem cells: from pituitary plasticity to adenoma development. Neuroendocrinology 94 265-277. (doi:10. 1159/000330857)
31. Fossmark R, Sordal O, Jianu CS, Qvigstad G, Nordrum IS, Boyce M & Waldum HL 2012 Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Alimentary Pharmacology & Therapeutics 36 1067-1075. (doi:10. 1111/apt. 12090)
32. Granberg D, Jacobsson H, Oberg K, Gustavsson J & Lehtihet M 2008 Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case report. Digestion 77 92-95. (doi:10. 1159/000122229)
33. Grozinsky-Glasberg S, Grossman AB & Gross DJ 2015 Carcinoid heart disease: from pathophysiology to treatment-'something in the way it moves'. Neuroendocrinology 101 263-273. (doi:10. 1159/000381930)
34. Hofland LJ & Lamberts SW 2003 The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocrine Reviews 24 28-47. (doi:10. 1210/er. 2000-0001)
35. Hofland LJ, de Herder WW, Waaijers M, Zuijderwijk J, Uitterlinden P, van Koetsveld PM & Lamberts SW 1999 Interferon-alpha-2a is a potent inhibitor of hormone secretion by cultured human pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 84 3336-3343. (doi:10. 1210/jc. 84. 9. 3336)
36. Hovind P, Simonsen L & Bulow J 2010 Decreased leg glucose uptake during exercise contributes to the hyperglycaemic effect of octreotide. Clinical Physiology and Functional Imaging 30 141-145. (doi:10. 1111/j. 1475-097X. 2009. 00917. x)
37. Huguet I, Grossman AB & O'Toole D 2015 Changes in epidemiology of NETs. Neuroendocrinology [in press]. (doi:10. 1159/000441897)
38. Ito T, Igarashi H & Jensen RT 2013 Zollinger-Ellison syndrome: recent advances and controversies. Current Opinion in Gastroenterology 29 650-661. (doi:10. 1097/MOG. 0b013e328365efb1)
39. Janson ET & Oberg K 1993 Long term management of carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncologica 32 225-229. (doi:10. 3109/02841869309083916)
40. Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, Scoazec JY, Salazar R, Sauvanet A, Kianmanesh R, et al. 2012 ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 95 98-119. (doi:10. 1159/000335591)
41. Kaltsas GA, Besser GM & Grossman AB 2004 The diagnosis and medical management of advanced neuroendocrine tumors. Endocrine Reviews 25 458-511. (doi:10. 1210/er. 2003-0014)
42. Kaltsas G, Androulakis II, de Herder WW & Grossman AB 2010 Paraneoplastic syndromes secondary to neuroendocrine tumours. Endocrine-Related Cancer 17 R173-R193. (doi:10. 1677/erc-10-0024)
43. Kindmark H, Sundin A, Granberg D, Dunder K, Skogseid B, Janson ET, Welin S, Oberg K & Eriksson B 2007 Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years. Medical Oncology 24 330-337. (doi:10. 1007/s12032-007-0011-2)
44. Korevaar TI, Ragazzoni F, Weaver A, Karavitaki N & Grossman AB 2014 IGF2-induced hypoglycemia unresponsive to everolimus. QJM 107 297-300. (doi:10. 1093/qjmed/hcr249)
45. Kulke MH, Bergsland EK & Yao JC 2009 Glycemic control in patients with insulinoma treated with everolimus. New England Journal of Medicine 360 195-197. (doi:10. 1056/NEJMc0806740)
46. Kulke MH, O'Dorisio T, Phan A, Bergsland E, Law L, Banks P, Freiman J, Frazier K, Jackson J, Yao JC, et al. 2014 Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocrine-Related Cancer 21 705-714. (doi:10. 1530/ ERC-14-0173)
47. Kvols LK, Martin JK, Marsh HM & Moertel CG 1985 Rapid reversal of carcinoid crisis with a somatostatin analogue. New England Journal of Medicine 313 1229-1230. (doi:10. 1056/nejm198511073131916)
48. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J & Hahn RG 1986 Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. New England Journal of Medicine 315 663-666. (doi:10. 1056/NEJM198609113151102)
49. Kvols LK, Oberg KE, O'Dorisio TM, Mohideen P, de Herder WW, Arnold R, Hu K, Zhang Y, Hughes G, Anthony L, et al. 2012 Pasireotide (SOM 230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocrine-Related Cancer 19 657-666. (doi:10. 1530/ ERC-11-0367)
50. Lew EA, Pisegna JR, Starr JA, Soffer EF, Forsmark C, Modlin IM, Walsh JH, Beg M, Bochenek W & Metz DC 2000 Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology 118 696-704. (doi:10. 1016/S0016-5085(00)70139-9)
51. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, et al. 2008 Gastroenteropancreatic neuroendocrine tumours. Lancet Oncology 9 61-72. (doi:10. 1016/S1470-2045(07)70410-2)
52. Modlin IM, Pavel M, Kidd M & Gustafsson BI 2010 Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Alimentary Pharmacology & Therapeutics 31 169-188.
53. Nahmias A, Grozinsky-Glasberg S, Salmon A & Gross DJ 2015 Pancreatic neuroendocrine tumors with transformation to insulinoma: an unusual presentation of a rare disease. Endocrinology, Diabetes & Metabolism Case Reports 2015 150032. (doi:10. 1530/edm-15-0032)
54. Nieto JM & Pisegna JR 2006 The role of proton pump inhibitors in the treatment of Zollinger-Ellison syndrome. Expert Opinion on Pharmacotherapy 7 169-175. (doi:10. 1517/14656566. 7. 2. 169)
55. Oberg K 2000 Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion 62 (Supplement 1) 92-97. (doi:10. 1159/000051862)
56. Ohn JH, Kim YG, Lee SH & Jung HS 2013 Transformation of nonfunctioning pancreatic neuroendocrine carcinoma cells into insulin producing cells after treatment with sunitinib. Endocrinology and Metabolism 28 149-152. (doi:10. 3803/EnM. 2013. 28. 2. 149)
57. O'Toole D, Ducreux M, Bommelaer G, Wemeau JL, Bouche O, Catus F, Blumberg J & Ruszniewski P 2000 Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 88 770-776. (doi:10. 1002/(sici)1097-0142(20000215)88:4<770::aidcncr6> 3. 0. co;2-0)
58. Papadogias D, Makras P, Kossivakis K, Kontogeorgos G, Piaditis G & Kaltsas G 2007 Carcinoid syndrome and carcinoid crisis secondary to a metastatic carcinoid tumour of the lung: a therapeutic challenge. European Journal of Gastroenterology & Hepatology 19 1154-1159. (doi:10. 1097/MEG. 0b013e3282294d88)
59. Pavel M, Horsch D, Caplin M, Ramage J, Seufferlein T, Valle J, Banks P, Lapuerta P, Sands A, Zambrowicz B, et al. 2015 Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. Journal of Clinical Endocrinology and Metabolism 100 1511-1519. (doi:10. 1210/ jc. 2014-2247)
60. Plockinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, Goede A, Caplin M, Oberg K, Reubi JC, et al. 2004 Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 80 394-424. (doi:10. 1159/000085237)
61. Qureshi SA, Burch N, Druce M, Hattersley JG, Khan S, Gopalakrishnan K, Darby C, Wong JL, Davies L, Fletcher S, et al. 2016 Screening for malnutrition in patients with gastro-entero pancreatic neuroendocrine tumours: a cross-sectional study. BMJ Open 6 e010765. (doi:10. 1136/bmjopen-2015-010765)
62. Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, Corrie P, Davar J, Davies AH, Lewington V, et al. 2012 Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 61 6-32. (doi:10. 1136/ gutjnl-2011-300831)
63. Rehfeld JF, Federspiel B & Bardram L 2013 A neuroendocrine tumor syndrome from cholecystokinin secretion. New England Journal of Medicine 368 1165-1166. (doi:10. 1056/NEJMc1215137)
64. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P & Anthony L 1999 Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. Journal of Clinical Oncology 17 600-606.
65. Ruszniewski P, Podevin P, Cadiot G, Marmuse JP, Mignon M, Vissuzaine C, Bonfils S & Lehy T 1993 Clinical, anatomical, and evolutive features of patients with the Zollinger-Ellison syndrome combined with type I multiple endocrine neoplasia. Pancreas 8 295-304. (doi:10. 1097/00006676-199305000-00003)
66. Saltz L, Trochanowski B, Buckley M, Heffernan B, Niedzwiecki D, Tao Y & Kelsen D 1993 Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 72 244-248. (doi:10. 1002/1097-0142(19930701)72:1<244::aidcncr2820720143> 3. 0. co;2-q)
67. Schubert ML & Peura DA 2008 Control of gastric acid secretion in health and disease. Gastroenterology 134 1842-1860. (doi:10. 1053/ j. gastro. 2008. 05. 021)
68. Somasundaram NP, Garusinghe C, Berney D & Grossman AB 2013 A thymic carcinoid tumour causing Zollinger-Ellison and Cushing's syndromes due to ectopic ACTH and gastrin secretion. Hormones 12 305-308. (doi:10. 14310/horm. 2002. 1149)
69. Song S, Shi R, Li B & Liu Y 2009 Diagnosis and treatment of pancreatic vasoactive intestinal peptide endocrine tumors. Pancreas 38 811-814. (doi:10. 1097/MPA. 0b013e3181b2bc7c)
70. Strosberg J, Weber J, Feldman M, Goldman J, Almhanna K & Kvols L 2013 Above-label doses of octreotide-LAR in patients with metastatic small intestinal carcinoid tumors. Gastrointestinal Cancer Research 6 81-85.
71. Strosberg JR, Benson AB, Huynh L, Duh M, Goldman J, Sahai V, Rademaker AW & Kulke MH 2014 Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist 19 930-936. (doi:10. 1634/ theoncologist. 2014-0120)
72. Thulin L, Samnegard H, Tyden G, Long DH & Efendic S 1978 Efficacy of somatostatin in a patient with carcinoid syndrome. Lancet 2 43. (doi:10. 1016/s0140-6736(78)91348-x)
73. Tirosh A, Stemmer SM, Solomonov E, Elnekave E, Saeger W, Ravkin Y, Nir K, Talmor Y & Shimon I 2016 Pasireotide for malignant insulinoma. Hormones 15 271-276.
74. Tomassetti P, Migliori M, Lalli S, Campana D, Tomassetti V & Corinaldesi R 2001 Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours. Annals of Oncology 12 (Supplement 2) S95-S99. (doi:10. 1093/annonc/12. suppl-2. s95)
75. Van der Lely AJ, de Herder WW & Lamberts SW 1997 A risk-benefit assessment of octreotide in the treatment of acromegaly. Drug Safety 17 317-324. (doi:10. 2165/00002018-199717050-00004)
76. Vashi PG, Gupta D & Dahlk S 2011 A unique case of a nonfunctional metastatic pancreatic neuroendocrine tumor transforming into an insulin-secreting tumor with an unusual clinical course. Pancreas 40 781-784. (doi:10. 1097/MPA. 0b013e318212c42d)
77. Vezzosi D, Bennet A, Rochaix P, Courbon F, Selves J, Pradere B, Buscail L, Susini C & Caron P 2005 Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. European Journal of Endocrinology 152 757-767. (doi:10. 1530/eje. 1. 01901)
78. Vinik A & Moattari AR 1989 Use of somatostatin analog in management of carcinoid syndrome. Digestive Diseases and Sciences 3 (Supplement) 145-275.
79. Wild D, Christ E, Caplin ME, Kurzawinski TR, Forrer F, Brandle M, Seufert J, Weber WA, Bomanji J, Perren A, et al. 2011 Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. Journal of Nuclear Medicine 52 1073-1078. (doi:10. 2967/jnumed. 110. 085142)
80. Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse MA, Tomassetti P, Weber MM, Fogelman DR, Ramage J, et al. 2015 Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug, Design, Development and Therapy 9 5075-5086. (doi:10. 2147/dddt. s84177)
81. Wood SM, Kraenzlin ME, Adrian TE & Bloom SR 1985 Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses. Gut 26 438-444. (doi:10. 1136/gut. 26. 5. 438)